Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XTX101 |
Synonyms | |
Therapy Description |
XTX101 is an anti-CTLA4 antibody engineered for tumor microenvironment-specific activity, which may lead to proliferation of CD8+ T lymphocytes, activation of T lymphocyte function, and tumor regression (Journal for ImmunoTherapy of Cancer 2020;8) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XTX101 | XTX 101|XTX-101 | CTLA4 Antibody 32 | XTX101 is an anti-CTLA4 antibody engineered for tumor microenvironment-specific activity, which may lead to proliferation of CD8+ T lymphocytes, activation of T lymphocyte function, and tumor regression (Journal for ImmunoTherapy of Cancer 2020;8) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04896697 | Phase Ib/II | XTX101 Pembrolizumab + XTX101 | XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |